PT  - JOURNAL ARTICLE
AU  - Antwi, Kwadwo
AU  - Fani, Melpomeni
AU  - Nicolas, Guillaume
AU  - Rottenburger, Christof
AU  - Heye, Tobias
AU  - Reubi, Jean Claude
AU  - Gloor, Beat
AU  - Christ, Emanuel
AU  - Wild, Damian
TI  - Localization of Hidden Insulinomas with <sup>68</sup>Ga-DOTA-Exendin-4 PET/CT: A Pilot Study
AID  - 10.2967/jnumed.115.157768
DP  - 2015 Jul 01
TA  - Journal of Nuclear Medicine
PG  - 1075--1078
VI  - 56
IP  - 7
4099  - http://jnm.snmjournals.org/content/56/7/1075.short
4100  - http://jnm.snmjournals.org/content/56/7/1075.full
SO  - J Nucl Med2015 Jul 01; 56
AB  - 111In-DOTA-exendin-4 SPECT/CT has been shown to be highly efficient in the detection of insulinomas. We aimed at determining whether novel PET/CT imaging with [Nle14,Lys40(Ahx-DOTA-68Ga)NH2]exendin-4 (68Ga-DOTA-exendin-4) is feasible and sensitive in detecting benign insulinomas. Methods: 68Ga-DOTA-exendin-4 PET/CT and 111In-DOTA-exendin-4 SPECT/CT were performed in a randomized cross-over order on 5 patients with endogenous hyperinsulinemic hypoglycemia. The gold standard for comparison was the histologic diagnosis after surgery. Results: In 4 patients histologic diagnosis confirmed a benign insulinoma, whereas one patient refused surgery despite a positive 68Ga-DOTA-exendin-4 PET/CT scan. In 4 of 5 patients, previously performed conventional imaging (CT or MR imaging) was not able to localize the insulinoma. 68Ga-DOTA-exendin-4 PET/CT correctly identified the insulinoma in 4 of 4 patients, whereas 111In-DOTA-exendin-4 SPECT/CT correctly identified the insulinoma in only 2 of 4 patients. Conclusion: These preliminary data suggest that the use of 68Ga-DOTA-exendin-4 PET/CT in detecting hidden insulinomas is feasible.